Vascular endothelial growth factor receptor-2 and its association with tumor immune regulatory gene expression in hepatocellular carcinoma

Anti-vascular endothelial growth factor (anti-VEGF) drugs have long been the only first-line treatment for advanced or unresectable hepatocellular carcinoma (HCC). Recently, the combination of bevacizumab (an anti-VEGF drug) and atezolizumab (an immune checkpoint blockade, ICB) has been proven to ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ze-Long, Zhu, Ling-Ling, Liu, Jing-Hua, Pu, Zhang-Ya, Ruan, Zhi-Ping, Chen, Jiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803564/
https://www.ncbi.nlm.nih.gov/pubmed/33223512
http://dx.doi.org/10.18632/aging.104119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803564/
https://www.ncbi.nlm.nih.gov/pubmed/33223512
http://dx.doi.org/10.18632/aging.104119

Ejemplares similares